Curr Opin Immunol. 2025 Jul 4;95:102599. doi: 10.1016/j.coi.2025.102599. Online ahead of print. ABSTRACT Autoinflammatory diseases are a group of immune dysregulation disorders, with genetic mutations identified in approximately 50% of patients. However, patients with known pathogenic mutations may display a broad range of phenotypic diversity. Epigenetic modifications play a crucial role in regulating immune-mediated diseases, … Read more

Curr Opin Immunol. 2025 Jul 3;95:102604. doi: 10.1016/j.coi.2025.102604. Online ahead of print. ABSTRACT Autoimmune hemolytic anemia (AIHA) is a rare disorder caused by loss of tolerance to red blood cell (RBC) antigens, leading to their destruction by autoantibodies. AIHA can occur as a primary condition or secondary to infections, malignancies, or immune-modulating therapies, such as … Read more

Curr Opin Immunol. 2025 Jul 3;95:102605. doi: 10.1016/j.coi.2025.102605. Online ahead of print. ABSTRACT PURPOSE OF THE REVIEW: Platelet and red blood cell (RBC) transfusions, whether used as prophylactic measures or therapeutic interventions, are critical for saving lives. However, the composition of platelet and RBC concentrates used for transfusion may contribute to adverse reactions following transfusion. … Read more

Curr Opin Immunol. 2025 Jul 2;95:102594. doi: 10.1016/j.coi.2025.102594. Online ahead of print. ABSTRACT Over recent decades, the significance of autoantibodies has been increasingly recognized in neurological diseases. Breakthroughs, such as the identification of pathogenic autoantibodies targeting aquaporin-4 in central nervous system demyelinating disorders and N-methyl-D-aspartate receptors in autoimmune encephalitis, have revolutionized both the discovery and … Read more

Curr Opin Immunol. 2025 Jul 2;95:102600. doi: 10.1016/j.coi.2025.102600. Online ahead of print. ABSTRACT Exhausted CD8+T cells (CD8+Tex), characterized by progressive dysfunction and sustained inhibitory receptor expression, emerge as a potential therapeutic target for autoimmune diseases. While Tex impairs antitumor immunity, the reduced autoreactivity prevents the functioning of pathogenic CD8⁺T cells, contrasting with broad immunosuppression from … Read more

Curr Opin Immunol. 2025 Jul 2;95:102603. doi: 10.1016/j.coi.2025.102603. Online ahead of print. ABSTRACT PURPOSE OF THE REVIEW: Recent insights into extracellular vesicles (EVs) derived from platelet (PC) and red blood cell concentrates (RBC), which form during blood product processing and storage. RECENT FINDINGS: EVs impact transfusion outcomes by modulating immune and inflammatory responses. Acting as … Read more

Curr Opin Immunol. 2025 Jul 1:102598. doi: 10.1016/j.coi.2025.102598. Online ahead of print. NO ABSTRACT PMID:40603234 | DOI:10.1016/j.coi.2025.102598

Curr Opin Immunol. 2025 Jun 27;95:102597. doi: 10.1016/j.coi.2025.102597. Online ahead of print. ABSTRACT Although we can at present more effectively manage Behçet syndrome compared to several decades ago, we are not yet quite near a cure. Our main shortcoming is we have yet to decipher its cause(s) and disease mechanism(s). First, there are reasons to … Read more

Curr Opin Immunol. 2025 Jun 24;95:102596. doi: 10.1016/j.coi.2025.102596. Online ahead of print. ABSTRACT Autoimmune diseases represent a significant global health burden, characterized by aberrant immune responses leading to tissue damage and functional impairment. Despite advancements in immunosuppressive therapies, achieving sustained remission remains challenging, necessitating innovative therapeutic approaches. Chimeric antigen receptor (CAR) T cell therapy, a … Read more

Curr Opin Immunol. 2025 Jun 23;95:102591. doi: 10.1016/j.coi.2025.102591. Online ahead of print. ABSTRACT Pemphigus and bullous pemphigoid (BP) are both autoimmune bullous diseases (AIBD), but their clinical features and treatment strategies are different. Pemphigus is characterized by intraepidermal blisters mediated by antibodies against desmosomes, while BP is characterized by subepidermal blisters mediated by antibodies against … Read more